Hepatitis autoinmune

  1. Sánchez Aldedhuelo, R. 1
  2. González Olivares, C. 1
  3. E. Sánchez Rodríguez 1
  4. Agustín Albillos Martínez
  1. 1 ervicio de Gastroenterología y Hepatología, Hospital Universitario Ramón y Cajal Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, España, IRYCIS, Madrid, España
Aldizkaria:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Argitalpen urtea: 2020

Zenbakien izenburua: Enfermedades del aparato digestivo (V)Enfermedades hepáticas. Hepatitis

Saila: 13

Zenbakia: 5

Orrialdeak: 245-254

Mota: Artikulua

DOI: 10.1016/J.MED.2020.03.002 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Medicine: Programa de Formación Médica Continuada Acreditado

Laburpena

Autoimmune hepatitis is a generally progressive, chronic liver disease, normally with fluctuating course, affecting both sexes of any age, mainly young women. Europe prevalence is 15-25 per 100,000 inhabitants. It is linked to other autoimmune conditions in 25% of patients. Although its pathogeny is still unknow, both genetics and environmental factors trigger a disorder of immune system regulation causing liver injury. The presentation of autoimmune hepatitis is heterogeneous, ranging from asymptomatic patients with abnormal liver functions tests to even fulminant hepatic failure. Diagnosis is complex and relies over clinical, biochemical and histologic findings. To rule out other etiologies is mandatory. Corticoids (prednisone) are the first-line treatment. Azathioprine is its maintenance treatment. Other immunosuppressants and even liver transplantation might be required when conventional therapy has failed or when disease progress.

Erreferentzia bibliografikoak

  • Lohse AW, Chazouilleres O, Dalekos G, Drenth J, Heneghan M, Hofer H, et al. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol. 2015;63:971-1004.
  • Ngu JH, Bechly K, Chapman BA, Burt MJ, Barclay ML, Gearry RB, et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol. 2010;25:1681-6.
  • Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60:612-7.
  • Czaja AJ. Autoimmune hepatitis in diverse ethnic populations and geographical regions. Expert Rev Gastroenterol Hepatol. 2013;7:365-85.
  • Chen J, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment Pharmacol Ther. 2014;39:117-24.
  • Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354:54-66.
  • Morillas R. Hepatitis autoinmune. En: Forns X, Solà R, editores. Monografías hepatología: Enfermedades hepáticas de base autoinmune. Madrid: Imaidea interactiva; 2015. p. 7-24.
  • Czaja AJ. Next‐generation transformative advances in the pathogenesis and management of autoimmune hepatitis. Aliment Pharmacology Therapeutics. 2017;46:920-37.
  • Manns MP, Lohse AW, Vergani D. Autoimmune hepatitis – Up-date 2015. J Hepatol. 2015;62:S1–S186.
  • Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepa-titis. Hepatology. 2010;51:2193-213.
  • Czaja AJ. Diagnosis and management of autoimmune hepatitis. Clin Liv Dis. 2015;19:57-79.
  • Gurung A, Assis DN, McCarty TR, Mitchell KA, Boyer JL, Jain D. Histologic features of autoimmune hepatitis: a critical appraisal. Hum Pathol. 2018;82:51-60.
  • Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and management of autoimmune hepa-titis. Hepatology. 2010;51:2193-13.
  • Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011;140:1980-9.
  • Trivedi PJ, Hubscher SG, Heneghan M, Gleeson D, Hirschfield GM. Grand round: Autoimmune hepatitis. J Hepatol. 2019;70:773-84.
  • Czaja AJ. Features and consequences of untreated type 1 autoimmune hepatitis. Liver Int. 2009;29:816-23.
  • Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatol. 2005;42:53-62.
  • Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159-85.
  • Soloway RD, Summerskill WH, Baggenstoss AH, Geall MG, Gitnick GL, Elveback IR, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820-33.
  • Gleeson D, Heneghan MA. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut. 2011;60:1611-29.
  • Manns MP, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterol. 2010;139:1198-206.
  • Czaja A. Review article: the management of autoinmmune hepatitis beyond consensus guidelines. Aliment Pharmacol Ther. 2013;38:343-64.
  • Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, et al. Budesonide in previously untreated autoimmune hepatitis. Liver Int. 2005;25:927-34.
  • Parker R, Oo YH, Adams DH. Management of patients with difficult autoimmune hepatitis. Ther Adv Gastroenterol. 2012;5:421-37.
  • Doycheva I, Watt KD, Gulamhusein AF. Autoimmune hepatitis: Current and future therapeutic options. Liver Int. 2019;39:1002-13.
  • Ma K, Berger D, Reau N. Liver diseases during pregnancy. Clin Liver Dis. 2019;23(2):345-61.
  • Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology. 2003;124: 9-17.
Datuen iturria: Dialnet